The view of the pharmaceutical industry |
| |
| Affiliation: | 1. Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan;2. Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan;3. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom;4. School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan;5. Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan;6. Department of Infectious Diseases, Osaka City General Hospital, Osaka, Japan;7. Department of Emergency Medicine, Kansai Rosai Hospital, Hyogo, Japan;8. Department of Pediatrics, Showa General Hospital, Tokyo, Japan;9. Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, Japan;10. Department of Emergency Medicine, Sagamihara Kyodo Hospital, Kanagawa, Japan;11. Department of Cardiology, Yokosuka General Hospital Uwamachi, Kanagawa, Japan;12. Intensive Care Unit, Ageo Central General Hospital, Saitama, Japan;13. Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan;14. Department of Emergency and Critical Care Medicine, Tokyo Metropolitan Police Hospital, Tokyo, Japan;15. Department of Critical Care Medicine, Yao Tokushukai General Hospital, Osaka, Japan;p. Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;q. Department of Internal Medicine, Sano Kosei General Hospital, Tochigi, Japan;r. Department of Emergency and Critical Care Medicine, Juntendo University Nerima Hospital, Tokyo, Japan;s. Department of Pulmonary Medicine, St. Luke’s International Hospital, Tokyo, Japan;t. Department of General Internal Medicine and Infectious Diseases, Saitama Medical Center, Saitama, Japan;u. Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan;v. Division of Critical Care Medicine, Nara Prefecture General Medical Center, Nara, Japan;w. Department of Internal Medicine, Kinan Hospital, Wakayama, Japan;x. Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan;y. Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital, Tokyo, Japan;z. Department of Infectious Diseases, Japanese Red Cross Medical Center, Tokyo, Japan;11. Department of Internal Medicine, Asahi General Hospital, Chiba, Japan;12. Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan;13. Department of Emergency and Critical Care Medicine, Tokyo Metropolitan TAMA Medical Center, Tokyo, Japan;14. Department of Emergency, Akita Red Cross Hospital, Akita, Japan;15. Department of Respiratory Medicine, Japan Community Health Care Organization Tokyo Yamate Medical Center, Tokyo, Japan;16. Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan;17. Department of Pulmonary Medicine, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan;18. Department of Emergency and Critical Care Medical Center, Osaka City General Hospital, Osaka, Japan;19. Department of Infectious Diseases, Showa General Hospital, Tokyo, Japan;110. Department of Emergency and General Internal Medicine, Yokosuka General Hospital Uwamachi, Kanagawa, Japan;111. Department of Pharmacy, Tokyo Metropolitan Police Hospital, Tokyo, Japan;112. Department of Respiratory Medicine, Tokyo Metropolitan Police Hospital, Tokyo, Japan;113. Department of Clinical Research, Yao Tokushukai General Hospital, Osaka, Japan;114. Clinical Research Support Center, Asahi General Hospital, Chiba, Japan;115. Non-Profit Organization Japan ECMO Network, Tokyo, Japan;1p. Department of Anesthesiology and Intensive Care, Osaka University Graduate School of Medicine, Suita, Japan;1q. Non-Profit Organization ICU Collaboration Network (ICON), Tokyo, Japan;1. Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands;2. National Reference Center of Rabies, Viral Diseases, Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium;1. Department of Infectious Diseases, Nagoya City East Medical Centre, Nagoya, Japan;2. Department of Pharmacy, Nagoya City East Medical Centre, Nagoya, Japan;3. Division of Parasitology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan;4. Department of Internal Medicine, Shin-Yamanote Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan |
| |
| Abstract: | Rhône-Poulenc Rorer has committed itself to the development of artemether because we believe the drug will be of considerable benefit to sufferers from severe falciparum malaria, and because it is a stable, effective and economical compound that can be given by intramuscular injection. The quality of the pharmaceutical product meets international regulatory standards. Artemether is unlikely to yield big profits, but we believe that major pharmaceutical companies have a responsibility to develop such much-needed products. To develop this project further, we will need the assistance of academic institutions, research organizations and international bodies. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
